ALK-Abello A/S Release: Positive Results From Pivotal Phase III Trial of New Allergy Immunotherapy Tablet Against House Dust Mite-Induced Allergic Asthma  
7/11/2013 9:21:43 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Copenhagen, Denmark; ALK (OMX: ALK.B) announces positive outcome of the second of two pivotal Phase III trials of its new allergy immunotherapy tablet for the treatment of house dust mite-induced respiratory diseases. The MITRA[1] trial meets its primary endpoint and demonstrates a significant reduction in the risk of moderate-to-severe asthma exacerbations.

Help employers find you! Check out all the jobs and post your resume.